XOMA ROYALTY CORPORATION (XOMA) Stock News
NASDAQ:XOMA - Nasdaq - US98419J2069 - Common Stock - Currency: USD
XOMA Latest News, Press Releases and Analysis
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of...
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty January 2025 Dividend Record and Payment Dates...
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets...
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent...
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
XOMA Royalty acquires 50% economic interest in portfolio of 60-plus early-stage assets with $15M payment to Twist Bioscience...
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
MIPLYFFA(TM) becomes 6th commercial asset in XOMA Royalty's portfolio...
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty to Present at Upcoming Investor Conferences in September
XOMA Royalty to Present at Upcoming Investor Conferences in September
EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members...
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips XOMA (NASDAQ:XOMA) just reported results for the second quarter of 2024.XOMA re...
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the...
XOMA Declares Quarterly Preferred Stock Dividends
XOMA Declares Quarterly Preferred Stock Dividends
July 2024 Dividends...
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an...
3 Crazy Good Stocks to Buy With $500 Right Now
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth.
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its...
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips XOMA (NASDAQ:XOMA) just reported results for the first quarter of 2024.XOMA rep...
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage...